Skip to main content
. 2018 Nov 24;10(12):467. doi: 10.3390/cancers10120467

Figure 1.

Figure 1

Kaplan–Meier analysis of progression-free survival (PFS) of patients treated with G/nab-P based on classification into one of three PGx profiles (A), and based on predicted G/nab-P sensitivity (B).